A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard of care (SOC) treatment following hospitalization for a COPD exacerbation
Chronic obstructive pulmonary disease (COPD) causes long-term breathing difficulties, and a severe flare-up can lead to an emergency hospital stay. Coming home from hospital can be an anxious time, as another flare-up often happens within a few months. This clinical trial is testing a medicine called dupilumab (also known as Dupixent) to see if it helps prevent future chest crises. Dupilumab is given as an injection under the skin. Researchers want to find out if taking dupilumab alongside standard COPD inhalers and treatments reduces the chance of emergency visits, readmissions, and severe breathing attacks. Half of the participants will receive dupilumab, and half will receive an inactive dummy medicine (placebo). Neither you nor your study doctor will know which one you are receiving. Everyone will continue to receive their standard medical care throughout the trial.
At a glance
What is this study about?
Chronic obstructive pulmonary disease, or COPD, is a long-term condition that inflames the airways and damages lung tissue, making it hard to breathe. People with COPD often experience sudden flare-ups, known as exacerbations, where coughing, phlegm, and breathlessness quickly get much worse. When a flare-up is severe, it can mean being admitted to hospital for emergency treatment. Unfortunately, having one bad flare-up puts you at a much higher risk of needing hospital care again soon after going home.
Dupilumab is an established medicine used for other inflammatory conditions, like severe asthma and eczema. It works by calming specific types of immune system inflammation that can irritate the airways. Researchers hope that adding dupilumab to regular COPD treatment will help heal the lungs after a hospital stay, making another flare-up less likely and helping people feel more in control of their breathing.
This trial compares dupilumab directly to a placebo (a dummy injection that contains no active medicine). By comparing two groups of patients who are both receiving their standard NHS COPD care, the study team can clearly see whether dupilumab makes a true difference to recovery, quality of life, and keeping people safely out of hospital.
Key takeaways
- Tests whether dupilumab injections stop COPD patients from needing emergency hospital care again.
- Designed for adults recently discharged from hospital after a severe COPD flare-up.
- Half of the participants receive dupilumab and half receive a dummy injection (placebo).
- You continue taking all of your normal COPD inhalers and treatments throughout the study.
- Your health and lung symptoms will be monitored very closely by specialist doctors.
Who may be eligible?
This trial is open to adults aged 18 and older who have been diagnosed with chronic obstructive pulmonary disease (COPD) and have recently been admitted to hospital due to a severe flare-up of their chest symptoms.
Both men and women may take part. Because the goal is to see if this treatment prevents repeat hospital visits, you must be in the recovery period following a hospital discharge for your COPD.
You might not be able to join if you have certain other medical conditions, severe infections, or are taking medications that clash with dupilumab. The trial doctor will review your full medical notes to ensure it is completely safe for you to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or over.
- I have been diagnosed with chronic obstructive pulmonary disease (COPD).
- I have recently been in hospital because of a sudden flare-up of my COPD.
- I am comfortable receiving injections under the skin.
- I am able to attend regular check-ups and fill in short daily symptom diaries.
What does participation involve?
If you decide to take part, you will be randomly assigned by a computer to receive either dupilumab or an identical-looking placebo injection. You will take this injection regularly under the skin, usually every two weeks, using a pre-filled syringe. You will be shown how to use it safely, or a nurse can help you.
Throughout the study, you will have regular check-ups with the trial team. These visits may involve breathing tests (spirometry), blood tests, and routine physical checks. You will also be asked to answer simple questions about your daily chest symptoms and how your breathing affects your everyday life using quick symptom diaries.
You will continue using your regular inhalers and usual COPD medicines as normal. The trial team will monitor your health closely, and if your breathing gets worse at any point, your doctor will treat you immediately. Total participation usually lasts several months to a year.
Potential risks and benefits
Locations (3)
- —UnverifiedBelgium
- —UnverifiedItaly
- —UnverifiedSpain
Common questions
What is a placebo?
A placebo is a dummy treatment designed to look identical to the real medicine, but with no active ingredients. It helps researchers prove whether the improvements seen are truly caused by the new drug.
Will I have to stop taking my regular COPD inhalers?
No. You will continue to take your standard daily COPD treatments and rescue inhalers exactly as prescribed by your doctor throughout the trial.
How is the study medicine given?
It is given as an injection just under the skin (subcutaneously) using a simple, pre-filled syringe, often into the thigh or tummy area.
Do I have to pay for anything to take part?
No. The trial medication, extra tests, and study appointments are completely free, and travel expenses to and from the hospital clinic are usually covered.
Can I leave the study if I change my mind?
Yes. Taking part is completely voluntary. You are free to withdraw at any point, and your standard medical care will carry on as normal.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.